. Author manuscript; available in PMC: 2009 Jun 1.

Published in final edited form as: J Reprod Immunol. 2007 Oct 24;78(1):58–67. doi: 10.1016/j.jri.2007.08.004

Table II.

Effect of depletion of Gr-1⁺ cells on protection mediated by passive transfer of HSV-specific polyclonal antibodies or monoclonal anti-gD2 10E4.2G2a antibodies

			Titer (PFU/ mg tissue)
Depletion^a	HSV-specific Ab Transferred^b	Incidence^c	Lumbosacral ganglia	Spinal Cord
A
Anti- Gr-1⁺	Polyclonal Ab	7 \ 11	754 +/− 502	616 +/− 162
Control IgG	Polyclonal Ab	3 \ 11 ^d	130 +/− 129	155 +/− 152
Anti- Gr-1⁺	None (PBS)	6 \ 6^e	1087 ^+/− 518	903 +/− 249
B
Anti- Gr-1⁺	10E4.2G2a	1 \ 14^d	49 +/− 49^d	45 +/− 45 ^d
Control IgG	10E4.2G2a	0 \ 14 ^d	0^d	0 ^d
Anti- Gr-1⁺	None (PBS)	12 \ 12	3475 +/− 723	1159 +/− 231

Rag 1 ^−/− mice were depleted of Gr-1⁺ cells by in vivo treatment with RB6.8C5 antibody or treated with an isotype control antibody of irrelevant specificity.

Mice received either 50µg HSV-specific polyclonal Ab (A), 50µg 10E4.2IgG2a antibody (B), or PBS as a control 2 days prior to ivag inoculation of 5×10³ PFU HSV-2 strain 186. Lumbosacral ganglia and spinal cords were sampled on day 8 post inoculation.

Results are expressed as the number of samples containing infectious virus per total number of samples. Results were pooled from 2 experiments of identical design.

p<0.05 compared to PBS-treated Gr-1 depleted mice, 2-tailed Fisher’s exact test.

Four PBS treated, anti-Gr-1 treated mice died prior to tissue sampling and were not included in the analysis.